Highlights
The interim analysis of the SACHI trial has revealed several critical findings for the management of advanced non-small-cell lung cancer (NSCLC):
- The combination of savolitinib and osimertinib achieved a 66% reduction in the risk of disease progression or death compared to standard platinum-based chemotherapy in both the third-generation TKI-naive and intention-to-treat populations.
- Median progression-free survival (PFS) was nearly doubled in the third-generation TKI-naive group (9.8 months vs. 5.4 months) and significantly improved in the overall population (8.2 months vs. 4.5 months).
- The safety profile of the oral combination was comparable to chemotherapy in terms of Grade 3 or higher adverse events, offering a more convenient treatment modality for patients.
- These results establish the savolitinib-osimertinib regimen as a potential new standard of care for patients with EGFR-mutated, MET-amplified NSCLC following TKI failure.
